We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » LEGAL RISKS ON THE RISE FOR CLINICAL TRIALS

LEGAL RISKS ON THE RISE FOR CLINICAL TRIALS

June 21, 2006

Everyone involved with clinical trials, including sponsors, sites and investigators, faces a complex landscape of criminal and civil legal risks, according to experts speaking at a recent industry conference.

Recent legal claims filed over clinical trials include fraud, failure to obtain informed consent, battery, negligence, breach of fiduciary duty, unjust enrichment, breach of contract, and breach of the right to be treated with dignity as a research subject, John Isidor of Schulman Associates Institutional Review Board said June 19 at the Drug Information Association annual conference in Philadelphia.

While the dignity claim might sound frivolous, he said, it resulted in an out-of-court settlement totaling several million dollars in a case brought by patients who had undergone amniocentesis as part of a clinical study. The payout occurred even though none of the women suffered any physical harm, Isidor said.

In another case, the court held that the informed consent document was a legal contract and that the investigator was serving as the sponsoring pharmaceutical company's agent, a view that many people in the industry would consider questionable, Isidor said. The result was that the judge ordered the company to provide the plaintiff with a drug for chronic fatigue syndrome free of charge for a year -- even though the plaintiff was, in fact, receiving a placebo.

Courts do reject some plaintiffs' arguments, Isidor said, citing two recent cases in which patients sued to force Amgen to restart a trial of its artificial GDNF treatment for Parkinson's disease. The court rejected the plaintiffs' claims of breach of contract, since the sponsor had the stated right to unilaterally shut down the trial.

The federal government pays close attention to the way trials are run, as well. Ann Begley of the law firm Kirkpatrick & Lockhart Nicholson said the FDA and the Office for Human Research Protections (OHRP) use their enforcement powers to protect clinical trial participants and ensure data integrity, although the OHRP's authority extends mainly to federally funded studies or to sites that have subjected themselves voluntarily to its rules. (http://www.fdanews.com/did/5_121/)

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Okami Medical’s LOBO-7 and LOBO-9 Vascular Occluders Cleared

  • FDA Puts Clinical Hold on Astellas Late-Onset Pompe Disease Clinical Trial

  • FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

  • Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing